表紙:細胞培養の市場規模、シェア、動向分析:製品別、用途別、エンドユーザー別、地域別展望、競争戦略、2030年までのセグメント別予測
市場調査レポート
商品コード
1070363

細胞培養の市場規模、シェア、動向分析:製品別、用途別、エンドユーザー別、地域別展望、競争戦略、2030年までのセグメント別予測

Cell Culture Market Size, Share & Trends Analysis By Product, By Application, By End User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

出版日: | 発行: SPER Market Research Pvt. Ltd. | ページ情報: 英文 223 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.89円
細胞培養の市場規模、シェア、動向分析:製品別、用途別、エンドユーザー別、地域別展望、競争戦略、2030年までのセグメント別予測
出版日: 2022年04月13日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 223 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の細胞培養の市場規模は、今後11.2%のCAGRで拡大し、2030年までに598億米ドルに達すると予測されています。感染症の流行や健康に対する意識の高まりが、ワクチンやモノクローナル抗体、個別化医療に向けた細胞培養の導入に影響を与えています。

当レポートでは、世界の細胞培養市場について調査し、市場の概要とともに、製品別、用途別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 成長要因、抑制要因、機会、課題の分析
    • 促進要因
    • 抑制要因
    • 市場の機会
    • 課題
  • COVID-19が細胞培養市場に及ぼす影響

第5章 市場変数と見通し

  • SWOT分析
    • 強み
    • 弱み
    • 機会
    • 脅威
  • PESTEL分析
    • 政治情勢
    • 経済情勢
    • 社会的情勢
    • 技術情勢
    • 環境情勢
    • 法的情勢
  • ポーターのファイブフォース分析
    • 売り手の交渉力
    • 買い手の交渉力
    • 代替の脅威
    • 新規参入者の脅威
    • 競争企業間の敵対関係
  • ヒートマップ分析

第6章 世界の細胞培養市場、製品別、2019年~2030年(100万米ドル)

  • 消耗品
    • 血清、メディア、および試薬
    • 容器
    • 付属品
  • 装置

第7章 世界の細胞培養市場、用途別、2019年~2030年(100万米ドル)

  • バイオ医薬品製造
    • モノクローナル抗体
    • ワクチン生産
    • その他の治療用タンパク質
  • 診断薬
  • 薬物のスクリーニング、開発
  • 組織エンジニアリング、再生医療
  • その他

第8章 世界の細胞培養市場、エンドユーザー別、2019年~2030年(100万米ドル)

  • 製薬会社、バイオテクノロジー企業
  • 病院、診断研究所
  • 研究・学術機関
  • その他

第9章 世界の細胞培養市場、地域別、2019年~2030年(100万米ドル)

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • 中東・アフリカ
    • サウジアラビア王国
    • アラブ首長国連邦
    • その他

第10章 企業プロファイル

  • Adolf Kuhner AG
  • Agilent Technologies, Inc
  • ANGUS Chemical Company
  • Becton, Dickinson and Company
  • Biospherix Ltd.
  • Caisson Laboratories Inc.
  • Cellexus
  • Corning Incorporated
  • Danaher Corporation
  • Eppendorf AG
  • FUJIFILM Irvine Scientific, Inc
  • Getinge AB
  • HiMedia Laboratories
  • InvivoGen
  • Lonza Group AG
  • Meissner Filtration Products Inc.
  • Merck KGaA
  • Miltenyi Biotec
  • Pan-Biotech GmbH
  • PromoCell GmbH
  • Sartorius AG
  • SeraCare Life Sciences Inc.
  • Solida Biotech GmbH
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific Inc.
目次
Product Code: BIOT2213

Global cell culture market is projected to be worth USD 59.8 billion by 2030.

According to SPER Market Research, the cell culture market estimated to reach USD 59.8 billion by 2030 with a CAGR of 11.2%. Rising prevalence of infectious diseases and growing awareness for health has influenced the adoption of cell culture for vaccines, monoclonal antibodies and personalized medicine.

Impact of COVID-19 on the Cell Culture Market

COVID-19 pandemic has prompted the development of vaccines for immunization. Cell culture has played an important role in the manufacturing of the vaccines against SARS-CoV-2. Cell culture provides safe and continuous production of substrates for viral vaccines. This development has impacted to the growth of the cell culture market.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030

Segments covered By Product, By Application, By End User

  • Geographies covered: North America, Europe, APAC, Latin America and the Middle East & Africa
  • Companies Covered: Adolf Kuhner AG, Agilent Technologies, Inc., ANGUS Chemical Company, Becton, Dickinson and Company, Biospherix Ltd., Caisson Laboratories Inc., Cellexus, Corning Incorporated, Danaher Corporation, Eppendorf AG, FUJIFILM Irvine Scientific, Inc., Getinge AB, HiMedia Laboratories, InvivoGen, Lonza Group AG, Meissner Filtration Products Inc., Merck KGaA, Miltenyi Biotec, Pan-Biotech GmbH, PromoCell GmbH, Sartorius AG, SeraCare Life Sciences Inc., Solida Biotech GmbH, STEMCELL Technologies Inc., Thermo Fisher Scientific Inc.

Driver: Rising awareness for cell-based vaccines

The prevalence of infectious diseases is rising globally. Cell culture technology can be used to prepare vaccines for various infectious diseases. The rising awareness for cell-based vaccines and their benefits is driving the growth of this market.

Restraints: High cost of research

Cell biology research consumes high quality reagents and equipment for providing accuracy in results. The regulatory approvals also insist the research to be done in highest quality to maintain standards. As a result, the research cost becomes very expensive which restraints the growth of this market.

Opportunity: Rising demand for 3D cell culture

The demand for 3D cell cultures is rising due to various advantages offered by 3D cell cultures as compared to 2D cell structures such as production of multi-dimensional cell cultures, better cell monitoring, greater stability and longer lifespan. Investors are also showing interest in this field which will significantly offer growth opportunities to this market.

Challenge: Generation of plastic waste

The cell culture relies on plastic consumables generating huge amount of plastic waste affecting the environment. The rising adoption of single-use bioprocessing systems is raising concerns related due to the disposal of solid waste materials. Recycling of such waste is not possible as it is composed of multiple plastic layers of polypropylene, nylon or polyethylene. The negative impact on the environment can be decreased in future with continuous research and development for eco-friendly equipment and techniques.

Cell Culture Market by Product:

Based on product, market has been segmented into Consumables (Sera, Media, and Reagents [Media (serum-free media, classical media & salts, stem cell culture media, specialty media, chemically defined media, and other media), Sera (fetal bovine sera (FBS), adult bovine sera (ABS), and other animal sera), Reagents (growth factors, supplements, buffers & chemicals, cell dissociation reagents, balanced salt solutions, attachment & matrix factors, antibiotics/antimycotics, contamination detection kits, cryoprotective agents, and other reagents)], Vessels [Roller/Roux Bottles, Cell Factory Systems/Cell Stacks, Multiwell Plates, Flasks, Petri Dishes], Accessories), Equipment (Supporting Equipment (filtration systems, cell counters, carbon dioxide incubators, centrifuges, autoclaves, microscopes, biosafety cabinets, and other supporting equipment such as pipetting aids, pipettes, cell inserts, cell scrapers, cell lifters, cell spreaders, pH meters, shakers, flow cytometers, and water baths), Bioreactors (conventional bioreactors, single-use bioreactors), Storage Equipment (Refrigerators & freezers, Cryostorage systems))

Cell Culture Market by Application:

Based on application, the market is segmented into Biopharmaceutical Production (Monoclonal antibodies, Vaccines production, Other therapeutic proteins), Diagnostics, Drug Screening & Development, Tissue Engineering & Regenerative Medicine (Cell and gene therapy, Other tissue engineering & regenerative medicine applications), Other Applications

Cell Culture Market by End User:

Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Research & Academic Institutes, Other End Users

Pharmaceutical & Biotechnological companies have the largest share of this market by end user due to highest consumption of cell culture equipment & consumables and expansion of manufacturing units to increase the production capacity.

Cell Culture Market by Region:

North America owns the largest share of this market owing to rising regulatory approvals for cell culture-based vaccines, rapidly evolving biotechnology and pharmaceutical sector, rising incidence of cancer, supportive government initiatives, technological advancements and rising investments in cell-based research and development.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary data
    • 2.1.2. Primary data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impact of the Cell Culture Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL analysis
    • 5.2.1. Political landscape
    • 5.2.2. Economic landscape
    • 5.2.3. Social landscape
    • 5.2.4. Technological landscape
    • 5.2.5. Environmental landscape
    • 5.2.6. Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of Buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat map analysis

6. Global Cell Culture Market, By Product, 2019-2030 (USD Million)

  • 6.1. Consumables
    • 6.1.1. Sera, Media, and Reagents
      • 6.1.1.1. Media (serum-free media, classical media & salts, stem cell culture media, specialty media, chemically defined media, and other media)
      • 6.1.1.2. Sera (fetal bovine sera (FBS), adult bovine sera (ABS), and other animal sera)
      • 6.1.1.3. Reagents (growth factors, supplements, buffers & chemicals, cell dissociation reagents, balanced salt solutions, attachment & matrix factors, antibiotics/antimycotics, contamination detection kits, cryoprotective agents, and other reagents)
    • 6.1.2. Vessels
      • 6.1.2.1. Roller/Roux Bottles
      • 6.1.2.2. Cell Factory Systems/Cell Stacks
      • 6.1.2.3. Multiwell Plates
      • 6.1.2.4. Flasks
      • 6.1.2.5. Petri Dishes
    • 6.1.3. Accessories
  • 6.2. Equipment
    • 6.2.1. Supporting Equipment (filtration systems, cell counters, carbon dioxide incubators, centrifuges, autoclaves, microscopes, biosafety cabinets, and other supporting equipment such as pipetting aids, pipettes, cell inserts, cell scrapers, cell lifters, cell spreaders, pH meters, shakers, flow cytometers, and water baths)
    • 6.2.2. Bioreactors (conventional bioreactors, single-use bioreactors)
    • 6.2.3. Storage Equipment (Refrigerators & freezers, Cryostorage systems)

7. Global Cell Culture Market, By Application, 2019-2030 (USD Million)

  • 7.1. Biopharmaceutical Production
    • 7.1.1. Monoclonal antibodies
    • 7.1.2. Vaccines production
    • 7.1.3. Other therapeutic proteins
  • 7.2. Diagnostics
  • 7.3. Drug Screening & Development
  • 7.4. Tissue Engineering & Regenerative Medicine
    • 7.4.1. Cell and gene therapy
    • 7.4.2. Other tissue engineering & regenerative medicine applications
  • 7.5. Other Applications

8. Global Cell Culture Market, By End User, 2019-2030 (USD Million)

  • 8.1. Pharmaceutical & Biotechnology Companies
  • 8.2. Hospitals & Diagnostic Laboratories
  • 8.3. Research & Academic Institutes
  • 8.4. Other End Users

9. Global Cell Culture Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. Adolf Kuhner AG
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Agilent Technologies, Inc.
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. ANGUS Chemical Company
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. Becton, Dickinson and Company
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Biospherix Ltd.
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. Caisson Laboratories Inc.
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Cellexus
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Corning Incorporated
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. Danaher Corporation
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Eppendorf AG
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. FUJIFILM Irvine Scientific, Inc.
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. Getinge AB
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. HiMedia Laboratories
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. InvivoGen
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. Lonza Group AG
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. Meissner Filtration Products Inc.
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. Merck KGaA
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. Miltenyi Biotec
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. Pan-Biotech GmbH
    • 10.19.1. Company details
    • 10.19.2. Financial outlook
    • 10.19.3. Product summary
    • 10.19.4. Recent developments
  • 10.20. PromoCell GmbH
    • 10.20.1. Company details
    • 10.20.2. Financial outlook
    • 10.20.3. Product summary
    • 10.20.4. Recent developments
  • 10.21. Sartorius AG
    • 10.21.1. Company details
    • 10.21.2. Financial outlook
    • 10.21.3. Product summary
    • 10.21.4. Recent developments
  • 10.22. SeraCare Life Sciences Inc.
    • 10.22.1. Company details
    • 10.22.2. Financial outlook
    • 10.22.3. Product summary
    • 10.22.4. Recent developments
  • 10.23. Solida Biotech GmbH
    • 10.23.1. Company details
    • 10.23.2. Financial outlook
    • 10.23.3. Product summary
    • 10.23.4. Recent developments
  • 10.24. STEMCELL Technologies Inc.
    • 10.24.1. Company details
    • 10.24.2. Financial outlook
    • 10.24.3. Product summary
    • 10.24.4. Recent developments
  • 10.25. Thermo Fisher Scientific Inc.
    • 10.25.1. Company details
    • 10.25.2. Financial outlook
    • 10.25.3. Product summary
    • 10.25.4. Recent developments